Promising Leukemia Treatment Results Point to a Clinical Breakthrough

Promising Leukemia Treatment Results Point to a Clinical Breakthrough

2026-11-16 companies

Seattle, Monday, 16 November 2026.
Aptevo Therapeutics reported that its lead therapy achieved a 79% remission rate in high-risk leukemia patients, nearly doubling historical benchmarks while the firm advances critical trials.

Seattle Biotech Firm Delivers Clinical Breakthrough in AML Treatment

Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biopharmaceutical company based in Seattle, announced on November 16, 2026, groundbreaking clinical results for its lead oncology candidate, mipletamig, in patients with high-risk TP53-mutated acute myeloid leukemia (AML). The company reported that mipletamig achieved a 79% complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) rate in 11 of 14 evaluable patients when combined with venetoclax and azacitidine [1]. This remission rate represents a significant improvement over the historical benchmark of 41%, effectively nearly doubling the efficacy of existing treatments for this aggressive cancer subtype [1][GPT].

Pipeline Advancement and Financial Health

Beyond the clinical milestone, Aptevo also highlighted progress in its pipeline, including the advancement of next-generation trispecific antibody candidates toward human testing [1]. The company’s third-quarter 2026 financial results, released concurrently with the clinical update, revealed a net loss of $6.5 million for the quarter ended September 30, 2026, with cash and cash equivalents totaling $8.3 million [1]. This represents a decrease from $9.8 million in cash as of June 30, 2026, reflecting the firm’s ongoing investment in research and development [1].

Key Clinical Milestones and Future Plans

The clinical data presented on November 16, 2026, underscores mipletamig’s potential as a transformative therapy for AML patients with TP53 mutations, a subgroup historically associated with poor prognosis. Notably, 10 of 47 patients receiving the combination therapy progressed to potentially curative allogeneic stem cell transplantation, further validating the treatment’s clinical utility [1]. Aptevo has also refined its priming-dose regimen, demonstrating improved tolerability with a significant reduction in infusion-related reactions [1]. Looking ahead, the company plans to complete its Phase 1b RAINIER dose optimization study by year-end 2026 and engage in regulatory interactions for mipletamig in the first half of 2027 [1].

Corporate Developments and Shareholder Initiatives

In a parallel corporate development, Aptevo’s board has called for a virtual special meeting of stockholders on December 14, 2026, to vote on several key proposals, including a potential reverse stock split ranging from 1-for-3 to 1-for-10 [2]. The company also seeks approval for the issuance of common stock and inducement warrants totaling 20% or more of outstanding shares to comply with Nasdaq Listing Rule 5635(d) [2]. As of November 11, 2026, Aptevo reported 2,671,923 shares of common stock outstanding, with shareholders entitled to one vote per share [2]. The board unanimously recommends voting in favor of all proposals, including the Sixth Amended and Restated 2018 Stock Incentive Plan [2].

Market and Investor Sentiment

Aptevo’s recent clinical and corporate developments have drawn attention from market analysts and investors. The company’s stock performance, as tracked on interactive price charts, reflects heightened interest in its pipeline and financial trajectory [3]. Analysts note that the firm’s focus on bispecific and trispecific immunotherapies positions it at the forefront of innovation in oncology, particularly in addressing unmet medical needs for solid tumors and hematologic malignancies [GPT].

Sources


Biotechnology Oncology